Lucius LuciBal Baloxavir marboxil 20mg

Product Information

• Product name: LuciBal Baloxavir marboxil 20mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Baloxavir Marboxil
• Current strength: 20mg
• SKU: LU-ITEM-139
• Site category: influenza, other cancer

Product Summary

LuciBal Baloxavir marboxil 20mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Baloxavir Marboxil is the active ingredient used for this product page. Public prescribing information for Baloxavir Marboxil was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Baloxavir marboxil is an antiviral drug with activity against influenza virus .

Reference Indications

Baloxavir Marboxil is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: Treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications . Post-exposure prophylaxis of influenza in patients 5 years of age and older following contact with an individual who has influenza. Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use Baloxavir Marboxil.

Reference Dosage and Administration

Recommended dosage and preparation of Baloxavir Marboxil for oral suspension (bottles) or for oral suspension (packets) for both for oral or enteral use in patients 5 years of age and older. Take Baloxavir Marboxil as a single dose as soon as possible and within 48 hours of influenza symptom onset for treatment of acute uncomplicated influenza or following contact with an individual who has influenza.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Hypersensitivity such as anaphylaxis, angioedema, urticaria, and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. Increased incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: Baloxavir Marboxil is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group . Risk of bacterial infection: Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. Baloxavir Marboxil has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

Common Adverse Reactions and Monitoring

Adverse events reported in at least 1% of adult and adolescent influenza subjects treated with Baloxavir Marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). Adverse events reported in at least 5% of pediatric subjects (5 to < 12 years) treated with Baloxavir Marboxil included vomiting (5%) and diarrhea (5%). The overall safety profile of Baloxavir Marboxil is based on data from 2,079 subjects, 5 years of age and older in 5 controlled clinical trials who received Baloxavir Marboxil.

Drug Interactions and Special Populations

Avoid coadministration of Baloxavir Marboxil with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). ( 2.1 , 7.1 ) Live attenuated influenza vaccines may be affected by antivirals. Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir , which may reduce Baloxavir Marboxil efficacy. Avoid coadministration of Baloxavir Marboxil with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc). Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Xofluza public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.